Table 1.
Participant characteristics
| n = 20 | Baseline (Pre-ART), median (IQR) | Genotyping (during ART) median (IQR) |
|---|---|---|
| HIV-1 RNA (cp/ml) | 302,000 (39,473; 744,150) | 136 (76; 300) |
| Immunological parameters | ||
| CD4+ T cells/µl | 105.5 (55.5; 286.8) | 294 (234; 364) |
| HLA-DR+ T cells/µl | 387 (177; 591) | 301 (128; 473) |
| Ratio CD4/CD8 | 0.21 (0.095; 0.42) | 0.56 (0.3; 0.56) |
| Antiretroviral treatment (ART) | ||
| Duration | ||
| BL → GT (days) | 237 (172; 318) | |
| BL → LOD (days) | 459 (342; 649) | |
| Regimens (%) | ||
| DRV/r + 2 NRTI | 12 | |
| ATV/r + 2 NRTI | 1 | |
| LPV/r + 2 NRTI | 2 | |
| EFV + 2 NRTI | 2 | |
| RAL/EVG + 2 NRTI | 2 | |
| DRV/r + DTG | 1 | |
Patient parameters were analyzed before ART initiation (base line = BL) and during persistent viremia at the time point of genotyping (GT). Flow cytometric determined CD4+ T-cell levels were obtained from routine diagnostics
ATV Atazanavir, DRV Darunavir, LPV Lopinavir, EFV Efavirenz, RAL Raltegravir, EVG Elvitegravir, DTG Dolutegravir, /r boosted with Ritonavir, IQR interquartile range, BL Baseline, GT genotyping, LOD limit of detection (<50 HIV-1 RNA cp/ml)